Back Avineuro Pharmaceuticals, Inc
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.
San Diego, CA – June 10th, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. AVN-211 was well tolerated and no adverse events were observed in Phase I studies. The compound demonstrated excellent exposure and half-life of more than 15 hours. Avineuro Pharmaceuticals, Inc. will present this data at ICAD 2009 in Vienna, Austria in July.
Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com